RC 218
Alternative Names: RC-218Latest Information Update: 12 Jul 2022
At a glance
- Originator RemeGen
- Class Bispecific antibodies; Eye disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Eye disorders